Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells

Mahadev Rao, Scott M. Atay, Vivek Shukla, Young Hong, Trevor Upham, R. Taylor Ripley, Julie A. Hong, Mary Zhang, Emily Reardon, Patricia Fetsch, Markku Miettinen, Xinmin Li, Cody J. Peer, Tristan Sissung, William D. Figg, Assunta De Rienzo, Raphael Bueno, David S. Schrump

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: Specificity protein 1 (SP1) is an oncogenic transcription factor overexpressed in various human malignancies. This study sought to examine SP1 expression in malignant pleural mesotheliomas (MPM) and ascertain the potential efficacy of targeting SP1 in these neoplasms. Experimental Design: qRT-PCR, immunoblotting, and immunohistochemical techniques were used to evaluate SP1 expression in cultured MPM cells and MPM specimens and normal mesothelial cells/pleura. MTS, chemotaxis, soft agar, β-galactosidase, and Apo-BrdUrd techniques were used to assess proliferation, migration, clonogenicity, senescence, and apoptosis inMPM cells following SP1 knockdown, p53 overexpression, or mithramycin treatment. Murine subcutaneous and intraperitoneal xenograft models were used to examine effects of mithramycin on MPM growth in vivo. Microarray, qRT-PCR, immunoblotting, and chromatin immunoprecipitation techniques were used to examine gene expression profiles mediated by mithramycin and combined SP1 knockdown/p53 overexpression and correlate these changes with SP1 and p53 levels within target gene promoters. Results: MPM cells and tumors exhibited higher SP1 mRNA and protein levels relative to control cells/tissues. SP1 knockdown significantly inhibited proliferation, migration, and clonogenicity of MPM cells. Mithramycin depleted SP1 and activated p53, dramatically inhibiting proliferation and clonogenicity of MPM cells. Intraperitoneal mithramycin significantly inhibited growth of subcutaneous MPM xenografts and completely eradicated mesothelioma carcinomatosis in 75% of mice. Mithramycin modulated genes mediating oncogene signaling, cell-cycle regulation, senescence, and apoptosis in vitro and in vivo. The growthinhibitory effects of mithramycin inMPMcells were recapitulated by combined SP1 knockdown/p53 overexpression. Conclusions: These findings provide preclinical rationale for phase II evaluation of mithramycin in patients with mesothelioma. Clin Cancer Res; 22(5); 1197-210.

Original languageEnglish
Pages (from-to)1197-1210
Number of pages14
JournalClinical Cancer Research
Volume22
Issue number5
DOIs
Publication statusPublished - 01-03-2016

Fingerprint

Plicamycin
Apoptosis
Proteins
Mesothelioma
Immunoblotting
Heterografts
Neoplasms
Malignant Mesothelioma
Galactosidases
Polymerase Chain Reaction
Pleura
Chromatin Immunoprecipitation
Protein Transport
Chemotaxis
Growth
Oncogenes
Transcriptome
Genes
Agar
Cell Cycle

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Rao, Mahadev ; Atay, Scott M. ; Shukla, Vivek ; Hong, Young ; Upham, Trevor ; Ripley, R. Taylor ; Hong, Julie A. ; Zhang, Mary ; Reardon, Emily ; Fetsch, Patricia ; Miettinen, Markku ; Li, Xinmin ; Peer, Cody J. ; Sissung, Tristan ; Figg, William D. ; De Rienzo, Assunta ; Bueno, Raphael ; Schrump, David S. / Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 5. pp. 1197-1210.
@article{b9adc34402024dba9df7ec80f96c4eae,
title = "Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells",
abstract = "Purpose: Specificity protein 1 (SP1) is an oncogenic transcription factor overexpressed in various human malignancies. This study sought to examine SP1 expression in malignant pleural mesotheliomas (MPM) and ascertain the potential efficacy of targeting SP1 in these neoplasms. Experimental Design: qRT-PCR, immunoblotting, and immunohistochemical techniques were used to evaluate SP1 expression in cultured MPM cells and MPM specimens and normal mesothelial cells/pleura. MTS, chemotaxis, soft agar, β-galactosidase, and Apo-BrdUrd techniques were used to assess proliferation, migration, clonogenicity, senescence, and apoptosis inMPM cells following SP1 knockdown, p53 overexpression, or mithramycin treatment. Murine subcutaneous and intraperitoneal xenograft models were used to examine effects of mithramycin on MPM growth in vivo. Microarray, qRT-PCR, immunoblotting, and chromatin immunoprecipitation techniques were used to examine gene expression profiles mediated by mithramycin and combined SP1 knockdown/p53 overexpression and correlate these changes with SP1 and p53 levels within target gene promoters. Results: MPM cells and tumors exhibited higher SP1 mRNA and protein levels relative to control cells/tissues. SP1 knockdown significantly inhibited proliferation, migration, and clonogenicity of MPM cells. Mithramycin depleted SP1 and activated p53, dramatically inhibiting proliferation and clonogenicity of MPM cells. Intraperitoneal mithramycin significantly inhibited growth of subcutaneous MPM xenografts and completely eradicated mesothelioma carcinomatosis in 75{\%} of mice. Mithramycin modulated genes mediating oncogene signaling, cell-cycle regulation, senescence, and apoptosis in vitro and in vivo. The growthinhibitory effects of mithramycin inMPMcells were recapitulated by combined SP1 knockdown/p53 overexpression. Conclusions: These findings provide preclinical rationale for phase II evaluation of mithramycin in patients with mesothelioma. Clin Cancer Res; 22(5); 1197-210.",
author = "Mahadev Rao and Atay, {Scott M.} and Vivek Shukla and Young Hong and Trevor Upham and Ripley, {R. Taylor} and Hong, {Julie A.} and Mary Zhang and Emily Reardon and Patricia Fetsch and Markku Miettinen and Xinmin Li and Peer, {Cody J.} and Tristan Sissung and Figg, {William D.} and {De Rienzo}, Assunta and Raphael Bueno and Schrump, {David S.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-14-3379",
language = "English",
volume = "22",
pages = "1197--1210",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

Rao, M, Atay, SM, Shukla, V, Hong, Y, Upham, T, Ripley, RT, Hong, JA, Zhang, M, Reardon, E, Fetsch, P, Miettinen, M, Li, X, Peer, CJ, Sissung, T, Figg, WD, De Rienzo, A, Bueno, R & Schrump, DS 2016, 'Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells', Clinical Cancer Research, vol. 22, no. 5, pp. 1197-1210. https://doi.org/10.1158/1078-0432.CCR-14-3379

Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells. / Rao, Mahadev; Atay, Scott M.; Shukla, Vivek; Hong, Young; Upham, Trevor; Ripley, R. Taylor; Hong, Julie A.; Zhang, Mary; Reardon, Emily; Fetsch, Patricia; Miettinen, Markku; Li, Xinmin; Peer, Cody J.; Sissung, Tristan; Figg, William D.; De Rienzo, Assunta; Bueno, Raphael; Schrump, David S.

In: Clinical Cancer Research, Vol. 22, No. 5, 01.03.2016, p. 1197-1210.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells

AU - Rao, Mahadev

AU - Atay, Scott M.

AU - Shukla, Vivek

AU - Hong, Young

AU - Upham, Trevor

AU - Ripley, R. Taylor

AU - Hong, Julie A.

AU - Zhang, Mary

AU - Reardon, Emily

AU - Fetsch, Patricia

AU - Miettinen, Markku

AU - Li, Xinmin

AU - Peer, Cody J.

AU - Sissung, Tristan

AU - Figg, William D.

AU - De Rienzo, Assunta

AU - Bueno, Raphael

AU - Schrump, David S.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: Specificity protein 1 (SP1) is an oncogenic transcription factor overexpressed in various human malignancies. This study sought to examine SP1 expression in malignant pleural mesotheliomas (MPM) and ascertain the potential efficacy of targeting SP1 in these neoplasms. Experimental Design: qRT-PCR, immunoblotting, and immunohistochemical techniques were used to evaluate SP1 expression in cultured MPM cells and MPM specimens and normal mesothelial cells/pleura. MTS, chemotaxis, soft agar, β-galactosidase, and Apo-BrdUrd techniques were used to assess proliferation, migration, clonogenicity, senescence, and apoptosis inMPM cells following SP1 knockdown, p53 overexpression, or mithramycin treatment. Murine subcutaneous and intraperitoneal xenograft models were used to examine effects of mithramycin on MPM growth in vivo. Microarray, qRT-PCR, immunoblotting, and chromatin immunoprecipitation techniques were used to examine gene expression profiles mediated by mithramycin and combined SP1 knockdown/p53 overexpression and correlate these changes with SP1 and p53 levels within target gene promoters. Results: MPM cells and tumors exhibited higher SP1 mRNA and protein levels relative to control cells/tissues. SP1 knockdown significantly inhibited proliferation, migration, and clonogenicity of MPM cells. Mithramycin depleted SP1 and activated p53, dramatically inhibiting proliferation and clonogenicity of MPM cells. Intraperitoneal mithramycin significantly inhibited growth of subcutaneous MPM xenografts and completely eradicated mesothelioma carcinomatosis in 75% of mice. Mithramycin modulated genes mediating oncogene signaling, cell-cycle regulation, senescence, and apoptosis in vitro and in vivo. The growthinhibitory effects of mithramycin inMPMcells were recapitulated by combined SP1 knockdown/p53 overexpression. Conclusions: These findings provide preclinical rationale for phase II evaluation of mithramycin in patients with mesothelioma. Clin Cancer Res; 22(5); 1197-210.

AB - Purpose: Specificity protein 1 (SP1) is an oncogenic transcription factor overexpressed in various human malignancies. This study sought to examine SP1 expression in malignant pleural mesotheliomas (MPM) and ascertain the potential efficacy of targeting SP1 in these neoplasms. Experimental Design: qRT-PCR, immunoblotting, and immunohistochemical techniques were used to evaluate SP1 expression in cultured MPM cells and MPM specimens and normal mesothelial cells/pleura. MTS, chemotaxis, soft agar, β-galactosidase, and Apo-BrdUrd techniques were used to assess proliferation, migration, clonogenicity, senescence, and apoptosis inMPM cells following SP1 knockdown, p53 overexpression, or mithramycin treatment. Murine subcutaneous and intraperitoneal xenograft models were used to examine effects of mithramycin on MPM growth in vivo. Microarray, qRT-PCR, immunoblotting, and chromatin immunoprecipitation techniques were used to examine gene expression profiles mediated by mithramycin and combined SP1 knockdown/p53 overexpression and correlate these changes with SP1 and p53 levels within target gene promoters. Results: MPM cells and tumors exhibited higher SP1 mRNA and protein levels relative to control cells/tissues. SP1 knockdown significantly inhibited proliferation, migration, and clonogenicity of MPM cells. Mithramycin depleted SP1 and activated p53, dramatically inhibiting proliferation and clonogenicity of MPM cells. Intraperitoneal mithramycin significantly inhibited growth of subcutaneous MPM xenografts and completely eradicated mesothelioma carcinomatosis in 75% of mice. Mithramycin modulated genes mediating oncogene signaling, cell-cycle regulation, senescence, and apoptosis in vitro and in vivo. The growthinhibitory effects of mithramycin inMPMcells were recapitulated by combined SP1 knockdown/p53 overexpression. Conclusions: These findings provide preclinical rationale for phase II evaluation of mithramycin in patients with mesothelioma. Clin Cancer Res; 22(5); 1197-210.

UR - http://www.scopus.com/inward/record.url?scp=84962264656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962264656&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-3379

DO - 10.1158/1078-0432.CCR-14-3379

M3 - Article

VL - 22

SP - 1197

EP - 1210

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -